文献速递浆细胞疾病淋巴瘤

浆细胞疾病家族史与MGUS、多发性骨髓瘤及系统性AL淀粉样变性患者生存改善相关

Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis.
PubMed 文献 · Leukemia · 2021-11-11

该研究回顾性分析了25423例患者(16744例MGUS、6194例MM、2955例AL淀粉样变性),其中2.7%报告有浆细胞疾病家族史。有家族史的患者在MGUS、MM和AL淀粉样变性中总生存均 consistently 更长(粗HR分别为0.52、0.68、0.60),调整基线特征后关联仍一致;MGUS患者中 Familial PCD 者进展风险更高(病因特异HR 1.9)。

要点

  • 有浆细胞疾病家族史的患者在MGUS、MM和AL淀粉样变性中总生存均更长。
  • MGUS患者中有家族史者进展为MM、AL淀粉样变性或淋巴增殖性疾病的风险更高,病因特异HR 1.9。
  • 这是首个在MGUS、MM和系统性AL淀粉样变性队列中显示家族史与总生存改善相关的研究。

核心结论

  • 在MGUS、MM和系统性AL淀粉样变性患者队列中,有浆细胞疾病家族史的患者总生存改善。

研究设计与样本

  • 回顾性研究,纳入25423例患者,包括16744例MGUS、6194例MM和2955例AL淀粉样变性。

主要发现

  • 2.7%的患者报告有浆细胞疾病家族史(定义为MGUS、MM或AL淀粉样变性)。
  • MGUS患者中有家族史者总生存更长,粗HR 0.52(95%CI 0.40-0.67,p<0.001)。
  • MM患者中有家族史者总生存更长,粗HR 0.68(95%CI 0.57-0.79,p<0.001)。
  • AL淀粉样变性患者中有家族史者总生存更长,粗HR 0.60(95%CI 0.43-0.84,p=0.003)。
  • MGUS患者中有家族史者进展为MM、AL淀粉样变性或淋巴增殖性疾病的风险更高,病因特异HR 1.9(95%CI 1.3-2.7,p<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The association between familial plasma cell disorders (PCD) and prognosis in patients with MGUS, multiple myeloma (MM), and systemic light chain (AL) amyloidosis has not been well described. This study retrospectively reviewed outcomes of 25,423 patients (16,744 MGUS, 6194 MM, 2955 AL amyloidosis). Overall, 2.7% of patients reported having a family member with a PCD (defined as MGUS, MM, or AL amyloidosis). Family history was documented in 94% of MGUS, 92% of MM, and 88% of AL amyloidosis patients. The overall survival was consistently longer in patients with versus without familial PCD (crude hazard ratios: 0.52, 95% CI 0.40-0.67, p < 0.001 for MGUS patients; 0.68, 95% CI 0.57-0.79, p < 0.001 for MM patients; 0.60, 95% CI 0.43-0.84, p = 0.003 for AL patients). This association remained consistent when adjusting for baseline patient and disease characteristics. In MGUS patients, the risk of progression to MM, AL amyloidosis, or a lymphoproliferative disorder was higher in patients with familial PCD when accounting for death as a competing risk (cause-specific HR 1.9, 95% 1.3-2.7, p < 0.001). This is the first study to demonstrate that in a cohort of MGUS, MM, and systemic AL amyloidosis, patients with a PCD family history have an improved overall survival.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Visram A, Vachon C, Baughn LB, et al. Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia. 2021. PMID: 34764424. doi:10.1038/s41375-021-01454-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。